HUMA

Humacyte Inc

0.6816

Aug 26 • 3:59 PM ET -0.0196 (-2.80%)

0.7082

Aftermarket • 5:57 PM ET +0.0266 (3.90%)

Healthcare Biotechnology USA Micro NASD

Aug 24, 8:05 AMHumacyte to file supplemental BLA in November 2026 to add dialysis access indication for ATEV after FDA discussions

Peers: OABI CAMP RNA TNXP UNCY WHWK MIST CNTX TENX KPTI

| Held by: VTI VXF IBB SCHA VHT PRFZ BUSM SCHB BTEC IBBQ

Scroll to Statements

Index	-
Market Cap	189.35M
Enterprise Value	175.48M
Income	-96.73M
Sales	2.12M
Book/sh	0.11
Cash/sh	0.29
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	184
IPO	Dec 01, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	89.31
P/B	6.06
P/C	2.37
P/FCF	-
EV/EBITDA	-
EV/Sales	82.77
Quick Ratio	5.74
Current Ratio	6.21
Debt/Eq	2.12
LT Debt/Eq	2.07
Option/Short	Yes / Yes

EPS (ttm)	-0.49
EPS next Y	-0.24
EPS next Q	-0.09
EPS this Y	-52.55%
EPS next Y	38.88%
EPS next 5Y	44.08%
EPS past 3/5Y	-30.53% 53.14%
Sales past 3/5Y	- -
EPS Y/Y TTM	-7.39%
Sales Y/Y TTM	159.29%
EPS Q/Q	35.12%
Sales Q/Q	34.88%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-41.09% -60.96%

Insider Own	7.69%
Insider Trans	0.08%
Inst Own	26.41%
Inst Trans	6.19%
ROA	-69.87%
ROE	-547.87%
ROIC	-100.85%
Gross Margin	-708.91%
Oper. Margin	-5240.78%
Profit Margin	-4560.82%
SMA20	1.71%
SMA50	-2.88%
SMA200	-29.14%
Trades

Shs Outstand	277.80M
Shs Float	256.44M
Short Float	12.45%
Short Ratio	2.89
Short Interest	31.94M
52W High	2.55 -73.27%
52W Low	0.53 29.56%
Volatility	12.51% 9.85%
ATR (14)	0.07
RSI (14)	50.01
Beta	2.47
Rel Volume	0.51
Avg Volume	11.05M
Volume	5,676,992

Perf Week	-7.25%
Perf Month	8.07%
Perf Quarter	-40.73%
Perf Half Y	-41.24%
Perf YTD	-29.04%
Perf Year	-53.63%
Perf 3Y	-80.91%
Perf 5Y	-93.78%
Perf 10Y	-
Recom	1.40
Target Price	1.85
Prev Close	0.70
Price	0.68
Change %	-2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-25	Initiated	Barclays	Overweight	$3.50
May-14-25	Resumed	H.C. Wainwright	Buy	$4
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$12 → $15
Dec-11-23	Initiated	H.C. Wainwright	Buy	$6
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral	$2.75 → $3.50
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight	$6
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight	$10 → $4
Oct-29-21	Initiated	Cowen	Outperform	$17
Sep-24-21	Initiated	Oppenheimer	Outperform	$16
Sep-22-21	Initiated	BTIG Research	Buy	$19
Sep-16-21	Initiated	Piper Sandler	Overweight	$17

Show Previous Ratings

Aug-24-26 08:00AM	Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions (GlobeNewswire)
Aug-19-26 08:00AM	Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results (GlobeNewswire) +26.34%
Aug-18-26 08:00AM	Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess Implantation; Cites Bioengineered Blood Vessel as "Revolutionary Advancement" (GlobeNewswire)
Aug-12-26 07:04PM	Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... (GuruFocus.com) -6.34% -17.29%
05:23PM	Humacyte, Inc. Q2 2026 Earnings Call Summary (Moby)
07:00AM	Loading…
07:00AM	Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-11-26 09:22AM	Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-07-26 08:00AM	Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 (GlobeNewswire)
Jul-27-26 08:00AM	Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting (GlobeNewswire) +7.89%
Jul-14-26 08:00AM	Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access (GlobeNewswire)
Jun-15-26 08:00AM	Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting (GlobeNewswire)
Jun-10-26 09:08PM	Humacyte, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -19.40%
08:55PM	Humacyte, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
06:48PM	HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses (Stocktwits)
04:01PM	Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients (GlobeNewswire)
03:52PM	Loading…
Jun-05-26 03:52PM	Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -9.40%
May-28-26 11:29AM	Are Medical Stocks Lagging Agilon Health (AGL) This Year? (Quartz) +11.30%
May-26-26 08:00AM	Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access (GlobeNewswire) +5.71%
May-20-26 08:00AM	Humacyte Announces Symvess is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (GlobeNewswire) +11.14%
May-13-26 07:02PM	Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ... (GuruFocus.com) +24.18% -11.50%
07:00AM	Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 08:00AM	Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer (GlobeNewswire) -9.00%
May-08-26 08:00AM	Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026 (GlobeNewswire)
Apr-27-26 08:00AM	Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 (GlobeNewswire) +15.13%
Apr-24-26 08:00AM	Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess (GlobeNewswire)
Apr-22-26 08:00AM	Humacyte Appoints Jim Mercadante as Chief Commercial Officer (GlobeNewswire) +6.97%
Apr-21-26 08:00AM	Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Trauma Repair (GlobeNewswire)
Apr-09-26 03:50PM	Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -6.83%
Mar-27-26 07:00AM	Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (GlobeNewswire) -13.21%
Mar-26-26 09:17AM	Humacyte Inc (HUMA) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -5.42%
08:00AM	Loading…
08:00AM	Humacyte Appoints Rick McElheny as Senior Vice President of Business Development (GlobeNewswire)
Mar-23-26 08:00AM	Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 (GlobeNewswire) +8.61%
Mar-19-26 08:31AM	Humacyte Receives Symvess Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia (GlobeNewswire) -19.42%
08:30AM	Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock (GlobeNewswire)
Mar-17-26 08:00AM	Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair (GlobeNewswire)
Mar-06-26 09:30AM	Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-02-26 08:00AM	Humacyte To Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 08:00AM	Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting (GlobeNewswire) -5.26%
Feb-10-26 06:00PM	Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks) -13.93%
Feb-09-26 08:00AM	Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels (GlobeNewswire) +30.02%
Feb-02-26 06:00PM	Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-08-26 08:00AM	Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications (GlobeNewswire)
Jan-07-26 09:40AM	Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? (Zacks) +11.11%
Jan-05-26 08:00AM	Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel (GlobeNewswire) +8.72%
Dec-22-25 08:00AM	Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess in Extremity Trauma Repair (GlobeNewswire)
Dec-16-25 08:00AM	Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital (GlobeNewswire) -5.08%
Dec-10-25 02:12PM	Humacyte (HUMA): Benchmark Remains Bullish on Stock (Insider Monkey)
Dec-05-25 09:30AM	Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? (Zacks) -5.38%
Nov-20-25 08:00AM	Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV) Clinical Results (GlobeNewswire)
Nov-14-25 09:30AM	Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views? (Zacks)
Nov-13-25 08:00AM	Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) (GlobeNewswire)
Nov-12-25 02:03PM	Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... (GuruFocus.com)
08:30AM	Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-25 07:30AM	Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result (GuruFocus.com) -5.19%
Nov-10-25 08:00AM	Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 (GlobeNewswire)
Nov-06-25 06:00PM	Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors (Zacks) -9.66%
08:00AM	Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 (GlobeNewswire)
Oct-30-25 06:00PM	Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
08:00AM	Humacyte Announces Publication of New Data Comparing Symvess to Autologous Vein in Extremity Arterial Trauma (GlobeNewswire)
Oct-24-25 06:00PM	Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-17-25 06:00PM	Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why (Zacks) +5.23%
Oct-14-25 06:15PM	Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors (Zacks)
Oct-07-25 06:15PM	Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors (Zacks) -33.67%
09:00AM	Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering (GlobeNewswire)
Oct-06-25 08:00AM	Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess (GlobeNewswire) +18.10%
Oct-01-25 06:15PM	Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know (Zacks)
Sep-29-25 08:00AM	Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus (GlobeNewswire)
Sep-22-25 06:15PM	Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Sep-18-25 07:00AM	Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) (GlobeNewswire) +16.99%
Sep-15-25 07:00AM	Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess (GlobeNewswire)
Aug-20-25 09:30AM	Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views? (Zacks)
Aug-12-25 03:03AM	Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... (GuruFocus.com)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -29.64%
08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-25 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (GlobeNewswire) +11.76%
Aug-06-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks)
Jul-31-25 06:00PM	Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -5.00%
Jul-25-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks) -5.24%
Jul-24-25 06:15PM	Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jul-23-25 08:00AM	Humacyte Announces First Symvess Sale to Military Treatment Facility (GlobeNewswire) +18.70%
Jul-18-25 06:00PM	Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know (Zacks)
Jul-15-25 06:15PM	Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today (Zacks) -7.69%
Jul-09-25 06:15PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jul-08-25 08:00AM	Humacyte announces Symvess ECAT Approval from U.S. Defense Logistics Agency (GlobeNewswire) +18.98%
Jul-07-25 09:08AM	Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus (Zacks) -5.26%
Jun-30-25 06:00PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks) +9.09%
Jun-25-25 06:15PM	Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know (Zacks)
Jun-18-25 06:00PM	Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know (Zacks)
Jun-09-25 08:00AM	Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting (GlobeNewswire)
Jun-02-25 08:00AM	Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 (GlobeNewswire)
May-30-25 09:30AM	Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
May-19-25 04:05PM	Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (GlobeNewswire) +11.66%
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +31.06%
07:30AM	Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 (GlobeNewswire)
Apr-30-25 06:00PM	Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy (Zacks)
Apr-24-25 06:00PM	Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note (Zacks)

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Ph.D.Dr. Laura E. Niklason M.D.

CFOMr. Dale A. Sander

Chief Medical OfficerDr. Shamik J. Parikh M.D.

SPHRMs. Sabrina Osborne GPHR

Chief Strategy OfficerMs. Lisa Molyneux

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Keith Anthony	Director	Aug 20 '26	Buy	0.69	10,000	6,930	40,000	Aug 21 04:05 PM
Jones Keith Anthony	Director	Aug 17 '26	Buy	0.59	30,000	17,820	30,000	Aug 19 04:00 PM
Sebelius Kathleen	Director	May 19 '26	Buy	0.88	56,818	50,000	148,025	May 20 04:33 PM
Constantino Michael T.	Director	May 18 '26	Buy	0.89	11,000	9,840	43,950	May 20 04:32 PM
Sander Dale A.	CFO and Chief Corp. Dev. Off	May 18 '26	Sale	0.90	45,887	41,147	267,213	May 20 04:31 PM
Parikh Shamik J	Chief Medical Officer	May 18 '26	Sale	0.90	45,887	41,147	272,713	May 20 04:30 PM
Sander Dale A.	Officer	May 18 '26	Proposed Sale	0.90	45,887	41,147		May 18 04:09 PM
Parikh Shamik J	Officer	May 18 '26	Proposed Sale	0.90	45,887	41,147		May 18 03:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUMA

Humacyte Inc

Upgrade your Finviz experience